NewAmsterdam Pharma in the spotlight (part 2)

Data deep dive on BROOKLYN and BROADWAY phase 3 trials

Since our previous Boutique Biotech report, NewAmsterdam Pharma surged over 50% (sorry if you missed it!). In that report, we covered the announcement of positive topline data from the Phase 3 BROOKLYN trial for obicetrapib. We correctly called the initial 14/2% hit the stock took as modest and not-at-all unexpected, given that Wall Street analysts ha…